Alexander R Moschen

List of Publications by Year in Descending Order

79 papers	10,932 citations	44 h-index	85 g-index
85 ext. papers	13,014 ext. citations	9.5 avg, IF	6.94 L-index

#	Paper	IF	Citations
79	Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines.. *Npj Vaccines*, **2022**, 7, 22	9.5	0
78	Lactobacillus reuteri-an old acquaintance takes on a new task in colorectal tumor surveillance.. *Cancer Cell*, **2022**, 40, 125-127	24.3	1
77	The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients.. *Current Oncology Reports*, **2022**, 1	6.3	2
76	Uterine microbiota plasticity during the menstrual cycle: Differences between healthy controls and patients with recurrent miscarriage or implantation failure.. *Journal of Reproductive Immunology*, **2022**, 151, 103634	4.2	1
75	Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**,	7.9	1
74	When the genome bluffs: a tandem duplication event during generation of a novel Agmo knockout mouse model fools routine genotyping. *Cell and Bioscience*, **2021**, 11, 54	9.8	5
73	Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study. *Journal of Crohnʼs and Colitis*, **2021**, 15, 43-54	1.5	12
72	Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. *Hepatology*, **2021**, 73, 833-842	11.2	71
71	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. *Gut*, **2021**, 70, 585-594	19.2	2
70	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. *EBioMedicine*, **2021**, 70, 103539	8.8	16
69	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.. *Scandinavian Journal of Gastroenterology*, **2021**, 1-8	2.4	2
68	IBD in the time of corona - vigilance for immune-mediated diseases. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 529-530	24.2	1
67	Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity. *Leukemia*, **2020**, 34, 1885-1897	10.7	9
66	Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease. *Liver International*, **2020**, 40, 1610-1619	7.9	7
65	Dietary lipids fuel GPX4-restricted enteritis resembling Crohnʼs disease. *Nature Communications*, **2020**, 11, 1775	17.4	44
64	Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD. *Frontiers in Immunology*, **2019**, 10, 1070	8.4	20
63	IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 185-196	24.2	170

62	The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell*, **2018**, 33, 954-964	24.3	314
61	Recovery of ethanol-induced depletion ameliorates alcoholic liver disease. *Gut*, **2018**, 67, 891-901	19.2	258
60	NAD metabolism fuels human and mouse intestinal inflammation. *Gut*, **2018**, 67, 1813-1823	19.2	56
59	Gut microbiome: a new player in gastrointestinal disease. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 472, 159-172	5.1	47
58	Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease. *Liver International*, **2018**, 38, 1095-1101	7.9	8
57	Nuclear orphan receptor NR2F6 as a safeguard against experimental murine colitis. *Gut*, **2018**, 67, 1434-1444	19.2	14
56	Weight Loss Induced by Bariatric Surgery Restricts Hepatic Expression. *Journal of Obesity*, **2018**, 2018, 7108075	3.7	5
55	Liver-Microbiome Axis in Health and Disease. *Trends in Immunology*, **2018**, 39, 712-723	14.4	81
54	Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. *Trends in Endocrinology and Metabolism*, **2017**, 28, 388-397	8.8	146
53	Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. *Diabetes*, **2017**, 66, 347-357	0.9	141
52	Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2974-2984	5.6	18
51	Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression. *Liver International*, **2017**, 37, 299-306	7.9	8
50	NAFLD and diabetes mellitus. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 32-42	24.2	434
49	Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. *Visceral Medicine*, **2016**, 32, 329-334	2.4	23
48	Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *Hepatology*, **2016**, 64, 955-65	11.2	172
47	Gut Microbiome, Obesity, and Metabolic Syndrome **2016**, 447-459		2
46	How does the microbiome affect liver disease?. *Clinical Liver Disease*, **2016**, 8, 123-126	2.2	4
45	Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. *Cell Host and Microbe*, **2016**, 19, 455-69	23.4	144

44	Food, immunity, and the microbiome. *Gastroenterology*, **2015**, 148, 1107-19	13.3	193
43	The role of lipocalin-2 in liver regeneration. *Liver International*, **2015**, 35, 1195-202	7.9	12
42	Gut microbiome and liver diseases **2015**, 411-420		1
41	Lipocalin-2 ensures host defense against Salmonella Typhimurium by controlling macrophage iron homeostasis and immune response. *European Journal of Immunology*, **2015**, 45, 3073-86	6.1	40
40	Gut Microbiome, Obesity and Metabolic Syndrome **2015**, 1-14		1
39	Adipose Tissue Inflammation **2014**, 93-103		
38	IL-37 protects against obesity-induced inflammation and insulin resistance. *Nature Communications*, **2014**, 5, 4711	17.4	143
37	Mechanisms behind the link between obesity and gastrointestinal cancers. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2014**, 28, 599-610	2.5	50
36	Evolving therapies for non-alcoholic steatohepatitis. *Expert Opinion on Drug Discovery*, **2014**, 9, 687-96	6.2	9
35	Microbiota and diabetes: an evolving relationship. *Gut*, **2014**, 63, 1513-21	19.2	461
34	The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. *Cell Metabolism*, **2014**, 20, 787-798	24.6	72
33	Non-alcoholic steatohepatitis: a microbiota-driven disease. *Trends in Endocrinology and Metabolism*, **2013**, 24, 537-45	8.8	118
32	Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. *Canadian Journal of Physiology and Pharmacology*, **2013**, 91, 867-72	2.4	47
31	Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. *Journal of Hepatology*, **2013**, 59, 1315-22	13.4	78
30	Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. *Liver International*, **2013**, 33, 624-32	7.9	40
29	Blockade of receptor activator of nuclear factor-Β (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. *Nature Medicine*, **2013**, 19, 358-63	50.5	169
28	Inflammation, cytokines and insulin resistance: a clinical perspective. *Archivum Immunologiae Et Therapiae Experimentalis*, **2013**, 61, 119-25	4	133
27	Adipocytokines and hepatocellular carcinoma. *Digestive Diseases*, **2012**, 30, 508-13	3.2	28

26	Dietary Factors: Major Regulators of the Gut's Microbiota. *Gut and Liver*, **2012**, 6, 411-6	4.8	110
25	Pathways of liver injury in alcoholic liver disease. *Journal of Hepatology*, **2011**, 55, 1159-61	13.4	69
24	Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. *Molecular Medicine*, **2011**, 17, 840-5	6.2	121
23	Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. *Hepatology*, **2011**, 53, 1819-29	11.2	64
22	A key role for Pre-B cell colony-enhancing factor in experimental hepatitis. *Hepatology*, **2011**, 54, 675-86	11.2	18
21	Relevance of TNF-[illegible]gene polymorphisms in nonalcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, **2011**, 5, 155-8	4.2	6
20	Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. *Current Pharmaceutical Design*, **2010**, 16, 1913-20	3.3	100
19	Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target. *Gastroenterology*, **2010**, 139, 1823-6	13.3	34
18	Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. *Gut*, **2010**, 59, 1259-64	19.2	173
17	Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2010**, 690, 95-101	3.3	46
16	Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*, **2010**, 52, 1836-46	11.2	1423
15	Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. *Journal of Hepatology*, **2009**, 51, 765-77	13.4	113
14	Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression?. *European Cytokine Network*, **2009**, 20, 1-6	3.3	12
13	Interferon-alpha controls IL-17 expression in vitro and in vivo. *Immunobiology*, **2008**, 213, 779-87	3.4	52
12	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends in Endocrinology and Metabolism*, **2008**, 19, 371-9	8.8	334
11	Inflammatory mechanisms in the regulation of insulin resistance. *Molecular Medicine*, **2008**, 14, 222-31	6.2	515
10	Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. *Clinical Science*, **2008**, 114, 275-88	6.5	176
9	Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2008**, 11, 620-5	3.8	14

8	Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. *Gastroenterology*, **2007**, 133, 80-90	13.3	363
7	Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. *Journal of Immunology*, **2007**, 178, 1748-58	5.3	650
6	Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. *Journal of Hepatology*, **2006**, 44, 537-43	13.4	79
5	How to modulate inflammatory cytokines in liver diseases. *Liver International*, **2006**, 26, 1029-39	7.9	90
4	Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nature Reviews Immunology*, **2006**, 6, 772-83	36.5	2193
3	Adiponectin and its receptors in patients with chronic hepatitis C. *Journal of Hepatology*, **2005**, 43, 929-36	13.4	86
2	The RANKL/OPG system and bone mineral density in patients with chronic liver disease. *Journal of Hepatology*, **2005**, 43, 973-83	13.4	81
1	Increased expression of CCL20 in human inflammatory bowel disease. *Journal of Clinical Immunology*, **2004**, 24, 74-85	5.7	148